UroGen Pharma (URGN) Equity Average (2017 - 2025)
UroGen Pharma (URGN) has disclosed Equity Average for 9 consecutive years, with -$110.4 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Average fell 1421.7% year-over-year to -$110.4 million, compared with a TTM value of -$110.4 million through Dec 2025, down 1421.7%, and an annual FY2025 reading of -$57.1 million, down 54.4% over the prior year.
- Equity Average was -$110.4 million for Q4 2025 at UroGen Pharma, down from -$104.4 million in the prior quarter.
- Across five years, Equity Average topped out at $86.4 million in Q1 2021 and bottomed at -$127.5 million in Q2 2023.
- Average Equity Average over 5 years is -$32.7 million, with a median of -$40.5 million recorded in 2022.
- The sharpest move saw Equity Average crashed 2277.5% in 2023, then soared 130.94% in 2024.
- Year by year, Equity Average stood at $20.0 million in 2021, then tumbled by 482.1% to -$76.3 million in 2022, then rose by 29.77% to -$53.6 million in 2023, then skyrocketed by 115.59% to $8.4 million in 2024, then crashed by 1421.7% to -$110.4 million in 2025.
- Business Quant data shows Equity Average for URGN at -$110.4 million in Q4 2025, -$104.4 million in Q3 2025, and -$69.9 million in Q2 2025.